(-)-PHENSERINE TARTRATE

This article discusses clinical trials investigating (-)-PHENSERINE TARTRATE, an investigational drug being studied for the treatment of Alzheimer’s disease and mild cognitive impairment. The trials aim to evaluate the drug’s effects on specific biological markers related to brain cell health, comparing it to donepezil, an approved Alzheimer’s medication. These studies focus on patients with early or mild forms of Alzheimer’s disease.

Related diseases and areas:

• Dementia Alzheimer’s type
• Cognitive disorder

(12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE

This article reviews clinical trials investigating (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE, also known as daraxonrasib or RMC-6236. Trials are evaluating this treatment in patients with RAS-mutated cancers, particularly non-small cell lung cancer and pancreatic cancer.

Related diseases and areas:

• Non-small cell lung cancer
• Ductal adenocarcinoma of pa…
• Pancreatic carcinoma metast…

(1R,4S)-4-(5-((S)-2-Iminioimidazolidin-4-Yl)-1,3,4- Oxadiazol-2-Yl)-6-Oxo-5,7- Diazaspiro[Bicyclo[3.2.1]Octane-2,1′-Cyclopropan]-7-Yl Sulfate

This article discusses a clinical trial investigating the use of a new drug called XNW4107 (containing the active substance (1R,4S)-4-(5-((S)-2-Iminioimidazolidin-4-Yl)-1,3,4- Oxadiazol-2-Yl)-6-Oxo-5,7- Diazaspiro[Bicyclo[3.2.1]Octane-2,1′-Cyclopropan]-7-Yl Sulfate) in treating hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). The study aims to compare the effectiveness and safety of XNW4107 with a standard treatment for these serious infections.

Related diseases and areas:

• Pneumonia bacterial

(2R,4R)-1-(3-Chloro-2-Fluorobenzyl)-4-((3-Fluoro-6-((5-Methyl-1H-Pyrazol-3-Yl)Amino)Pyridin-2-Yl)Methyl)-2-Methylpiperidine-4-Carboxylic Acid

This article discusses a Phase 1 clinical trial investigating the use of LY3295668 Erbumine, an Aurora Kinase A inhibitor, in patients with relapsed or refractory neuroblastoma. The study aims to determine the recommended Phase 2 dose of the drug, both as a single agent and in combination therapy, while evaluating its safety, tolerability, and potential effectiveness against neuroblastoma tumors.

Related diseases and areas:

• Neuroblastoma

(2R)-N-[3-(5-Fluoro-2-{[2-Fluoro-3-(Methylsulfonyl)Phenyl]Amino}-4-Pyrimidinyl)-1H-Indol-7-Yl]-3-Methoxy-2-(4-Methyl-1-Piperazinyl)Propanamide-1-Hydroxy-2-Naphthoic Acid

This article discusses recent clinical trials investigating the use of AZD4604, a novel drug developed by AstraZeneca, for the treatment of moderate to severe asthma. AZD4604 is being studied as a potential new therapy for patients whose asthma is not well-controlled with current treatments. The trials aim to evaluate the safety and effectiveness of AZD4604 in improving lung function, reducing inflammation, and controlling asthma symptoms in adult patients.

Related diseases and areas:

• Asthma

(2S,3R,4R,5S)-1-[5-(2-FLUORO-BIPHENYL-4-YLMETHOXY)-PENTYL]-2-HYDROXYMETHYL-PIPERIDINE-3,4,5-TRIOL

This article discusses a clinical trial investigating (2S,3R,4R,5S)-1-[5-(2-FLUORO-BIPHENYL-4-YLMETHOXY)-PENTYL]-2-HYDROXYMETHYL-PIPERIDINE-3,4,5-TRIOL (also known as AZ-3102), a substance currently under evaluation. The Phase 1 study aims to understand how the body absorbs, processes, and eliminates this compound in healthy male volunteers. Researchers are examining the routes and rates of elimination through urine and feces.

Related diseases and areas:

• Lysosomal storage disorder

(2S)-2-[[2-[[(2S)-5-AMINO-2-[[(2S)-2-AMINOPROPANOYL]AMINO]-5-OXOPENTANOYL]AMINO]ACETYL]AMINO]-3-METHYLBUTANOIC ACID

Clinical trials are investigating “(2S)-2-[[2-[[(2S)-5-AMINO-2-[[(2S)-2-AMINOPROPANOYL]AMINO]-5-OXOPENTANOYL]AMINO]ACETYL]AMINO]-3-METHYLBUTANOIC ACID” in patients with coronary artery disease. The study is designed to evaluate whether it can affect recovery after on-pump coronary artery bypass grafting surgery, with a focus on hospital stay after surgery.

(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE

This article discusses clinical trials investigating (2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE, also known as zoldonrasib or RMC-9805, for treating non-small cell lung cancer with RAS G12D mutations. These Phase 2 trials evaluate the safety, tolerability, and effectiveness of this treatment alone or combined with other anticancer drugs in patients who have specific genetic mutations in their tumors.

Related diseases and areas:

• Non-small cell lung cancer

(3-BENZYL-3-METHYL-2,3-DIHYDROBENZOFURAN-6- YL)(PIPERIDIN-1-YL)METHANONE

This article discusses clinical trials investigating (3-BENZYL-3-METHYL-2,3-DIHYDROBENZOFURAN-6-YL)(PIPERIDIN-1-YL)METHANONE, also known as NTRX-07, for patients with cognitive disorders. The research evaluates the safety, tolerability, and effects of this experimental treatment in individuals with mild cognitive impairment and Alzheimer’s disease through controlled clinical studies.

Related diseases and areas:

• Cognitive disorder
• Dementia Alzheimer’s type

(3S,3’S,3A’s,10A’s)-6-Chloro-3′-(3-Chloro-2-Fluorophenyl)-1′-(Cyclopropylmethyl)-6′-Methyl-2-Oxo-1,2,3′,3A’,10′,10A’-Hexahydro-1’H-Spiro[Indole-3,2′-Pyrrolo[2′,3′:4,5]Pyrrolo[1,2-B]Indazole]-7′-Carboxylic Acid

This article summarizes clinical trials investigating the use of BI 907828 (also known as brigimadlin) in treating various advanced solid tumors. BI 907828 is a novel drug that acts as an MDM2-p53 antagonist, potentially offering a new approach to cancer treatment. The trials focus on evaluating its safety, efficacy, and tolerability in patients with dedifferentiated liposarcoma, biliary tract cancer, pancreatic cancer, lung cancer, and other solid tumors.

Related diseases and areas:

• Neoplasm
• Lung adenocarcinoma
• Pancreatic carcinoma
• Dedifferentiated liposarcoma
• Bladder cancer
• Biliary neoplasm

(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S,34R)-30-Ethyl-34-[(E,2R)-Hex-4-En-2-Yl]-4,7,10,12,15,19,25,28-Octamethyl-33-(Methylamino)-6,9,18,24-Tetrakis(2-Methylpropyl)-3,21-Di(Propan-2-Yl)-1-Oxa-4,7,10,13,16,19,22,25,28,31-Decazacyclotetratriacontane-2,5,8,11,14,17,20,23,26,29,32-Undecone Hydrochloride

This article discusses a clinical trial investigating the use of Isocyclosporin A eye drops for treating Atopic Keratoconjunctivitis (AKC). The study aims to evaluate the safety and effectiveness of two different dosages of Isocyclosporin A eye drop solution compared to a placebo (vehicle) in adult patients with AKC. The trial is designed to assess improvements in symptoms such as ocular itching, tearing, and discomfort, as well as signs like conjunctival hyperemia and corneal health. This research could potentially lead to new treatment options for individuals suffering from this challenging eye condition.

Related diseases and areas:

• Atopic keratoconjunctivitis

(3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-Hydroxy-2-Phenyl-1,2,3,4-Tetrahydronaphthalen-1-Yl]Phenyl]Piperidin-4-Yl]Methyl]Piperazin-1-Yl]-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione

This article summarizes several clinical trials investigating vepdegestrant (ARV-471), an oral medication being studied for the treatment of advanced or metastatic estrogen receptor-positive (ER+), HER2-negative breast cancer. Vepdegestrant is a new type of drug called a proteolysis targeting chimera (PROTAC) that works by degrading the estrogen receptor. The trials are evaluating vepdegestrant alone and in combination with other cancer drugs to determine its safety, effectiveness, and optimal dosing in patients whose cancer has progressed after prior treatments.

Related diseases and areas:

• Breast cancer
• Breast cancer metastatic

(4R)-1-[(5-Chloro-1H-1,2,4-Triazol-1-Yl)Methyl]-4-(3,4,5-Trifluorophenyl)-2-Pyrrolidinone

A clinical trial is underway to assess the potential of ABBV-552, a new drug developed for treating mild Alzheimer’s disease. This study aims to evaluate the safety, effectiveness, and how the body processes ABBV-552 in patients aged 50 to 90 years. The trial involves a randomized, double-blind, placebo-controlled design to thoroughly investigate the drug’s impact on cognitive function and overall disease progression in individuals with mild Alzheimer’s disease.

Related diseases and areas:

• Dementia Alzheimer’s type

(4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One

This article discusses clinical trials investigating (4R)-4-(3-(18F)Fluoranyl-5-Fluorophenyl)-1-[(3-Methylpyridin-4-Yl)Methyl]Pyrrolidin-2-One, a radioactive imaging agent used in brain scans. The trials aim to evaluate how this substance can help measure synaptic density (the number of connections between brain cells) in patients with Alzheimer’s disease, and how it relates to tau protein buildup in the brain.

Related diseases and areas:

• Dementia Alzheimer’s type

(6E)-6-[(6-Chloro-2-Methyl-2H-Indazol-5-Yl)Imino]-3-[(1-Methyl-1H-1,2,4-Triazol-3-Yl)Methyl]-1-[(2,4,5-Trifluorophenyl)Methyl]-1,3,5-Triazinane-2,4-Dione

This article discusses a clinical trial investigating the use of S-217622, a new protease inhibitor developed by Shionogi, for the treatment of hospitalized COVID-19 patients. The study aims to determine if a 5-day treatment course with S-217622, compared to a placebo, can improve clinical outcomes when given alongside standard care. This multicenter, adaptive, randomized, controlled trial is part of the STRIVE platform, which focuses on evaluating strategies and treatments for respiratory infections and viral emergencies.

Related diseases and areas:

• COVID-19

(6S,9As)-8-((6-(3-(4-Ethyl-1-Piperazinyl)-1-Azetidinyl)-2-Pyridinyl)Methyl)-6-((2-Fluoro-4-Hydroxyphenyl)Methyl)Hexahydro-4,7-Dioxo-N-(Phenylmethyl)-2-(2-Propen-1-Yl)-2H-Pyrazino(2,1-C)(1,2,4)Triazine-1(6H)-Carboxamide

E7386 is an innovative drug currently being studied in clinical trials for the treatment of various solid tumors, including colorectal cancer, hepatocellular carcinoma, and endometrial cancer. These trials aim to assess the safety, tolerability, and efficacy of E7386 when used alone or in combination with other anticancer drugs. The studies focus on patients who have previously received treatment for their cancer and are looking for new therapeutic options.

Related diseases and areas:

• Endometrial cancer
• Colorectal cancer
• Malignant melanoma
• Neoplasm
• Hepatocellular carcinoma

(Phosphonooxy)Methyln-[(S)-[1-(Bicyclo[1.1.1]Pentan1-Yl)-1H-1,2,3-Triazol-4-Yl](2-Methyl-1-Oxo-1,2-Dihydroisoquinolin-5-Yl)Methyl]-N-{8-Chloro-3-Cyano-4-[(2,2-Dimethylpropyl)Amino]Quinolin-6-Yl]Carbamate

This article discusses a Phase 2 clinical trial investigating the use of GS-5290, a new drug for patients with moderate to severe ulcerative colitis. The study aims to evaluate the efficacy and safety of GS-5290 compared to a placebo. This double-blinded, randomized, and placebo-controlled trial will assess various aspects of the drug’s performance, including its ability to induce clinical response, remission, and improve endoscopic and histologic outcomes in patients with ulcerative colitis.

Related diseases and areas:

• Colitis ulcerative

(R)-1-(Tert-Butyl)-N-(8-(2-((1-Methyl-1H-Pyrazol-4-Yl)Amino)Pyrimidin-4-Yl)-2-(Oxetan-3-Yl)-2,3,4,5-Tetrahydro-1H-Benzo[C]Azepin-5-Yl)-1H-1,2,3-Triazole-4-Carboxamide

A new clinical trial is underway to investigate the safety and effectiveness of BIIB091, a potential treatment for relapsing forms of multiple sclerosis (MS). This study, known as FUSION, aims to evaluate BIIB091 both as a standalone therapy and in combination with diroximel fumarate (DRF). The trial focuses on assessing the drug’s impact on brain inflammation and its overall safety profile in adults with relapsing MS.

Related diseases and areas:

• Relapsing multiple sclerosis

(R)-6-((3,3-DIFLUORO-1-METHYLPIPERIDIN-4-YL)OXY)-N-(3-ETHYNYL-2-FLUOROPHENYL)-7-METHOXYQUINAZOLIN-4-AMINE-FUMARATE (2:1)

This article discusses a clinical trial investigating WSD0922-FU (also known as (R)-6-((3,3-DIFLUORO-1-METHYLPIPERIDIN-4-YL)OXY)-N-(3-ETHYNYL-2-FLUOROPHENYL)-7-METHOXYQUINAZOLIN-4-AMINE-FUMARATE (2:1)) for patients with non-small cell lung cancer (NSCLC) who have a specific genetic mutation called C797S. The trial aims to evaluate the safety and effectiveness of this investigational treatment in this targeted patient population.

Related diseases and areas:

• Non-small cell lung cancer

(R)-N-(4-([1,2,4]-TRIAZOLO[1,5-C]-PYRIMIDIN-7-YLOXY)-3-METHYLPHENYL)-5-((3,3-DIFLUORO-1-METHYLPIPERIDIN-4-YL)OXY)-6-METHOXYQUINAZOLIN-4-AMINE

Clinical trials are studying “(R)-N-(4-([1,2,4]-TRIAZOLO[1,5-C]-PYRIMIDIN-7-YLOXY)-3-METHYLPHENYL)-5-((3,3-DIFLUORO-1-METHYLPIPERIDIN-4-YL)OXY)-6-METHOXYQUINAZOLIN-4-AMINE” in people with pretreated, unresectable, locally advanced or metastatic HER2-positive breast cancer, with or without CNS metastases. The main goal is to compare effectiveness and safety against an active treatment and measure progression-free survival.

Related diseases and areas:

• HER2 positive breast cancer

(R)‑Tetrahydrofuran‑3‑Yl 4‑(6‑(5‑(4‑Ethoxy‑1‑Isopropylpiperidin‑4‑Yl)Pyridin-2-Yl)Pyrrolo[1,2-B]Pyridazin-4-Yl)Piperazine-1-Carboxylate Sesquisuccinate

This article discusses the ongoing clinical trials of fidrisertib (IPN60130), a promising drug being studied for the treatment of Fibrodysplasia Ossificans Progressiva (FOP). FOP is a rare genetic disorder characterized by the formation of extra bone in muscles and connective tissues. The trials aim to assess the safety and effectiveness of fidrisertib in both children and adults with FOP, focusing on its ability to inhibit new bone formation and improve patients’ quality of life.

Related diseases and areas:

• Fibrodysplasia ossificans p…

(S)-2-(2′,5′-DIFLUORO-[1,1′-BIPHENYL]-4-YL)-N-METHYL-N-(4-METHYL-5-(S-METHYLSULFONIMIDOYL)THIAZOL-2-YL)ACETAMIDE

Clinical trials are investigating (S)-2-(2′,5′-DIFLUORO-[1,1′-BIPHENYL]-4-YL)-N-METHYL-N-(4-METHYL-5-(S-METHYLSULFONIMIDOYL)THIAZOL-2-YL)ACETAMIDE, also known as IM-250, for the treatment of recurrent genital herpes. The trials aim to evaluate the safety and efficacy of weekly administration in patients experiencing repeated outbreaks of this viral infection.

Related diseases and areas:

• Genital herpes simplex

(S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE

(S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE (also known as NSC001) is being investigated in clinical trials for the treatment of Alzheimer’s disease. This article discusses ongoing Phase 2 research evaluating the safety, tolerability, and potential efficacy of this substance in patients with mild to moderate Alzheimer’s disease.

Related diseases and areas:

• Nervous system disorder
• Dementia Alzheimer’s type

(S)-2-Hydroxy-6-((4-(2-(2-Hydroxyethyl)Nicotinoyl)Morpholin-3-Yl)Methoxy)Benzaldehyde

This article discusses the ongoing clinical trials of GBT021601, also known as (S)-2-Hydroxy-6-((4-(2-(2-Hydroxyethyl)Nicotinoyl)Morpholin-3-Yl)Methoxy)Benzaldehyde, a potential new treatment for Sickle Cell Disease (SCD). The trials aim to evaluate the drug’s effectiveness, safety, and impact on patients’ quality of life across different age groups, from infants to adults.

Related diseases and areas:

• Sickle cell disease

(S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid

This article discusses the clinical trials of a new topical medication, (S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid gel, also known as N-Acetyl-GED-0507-34-Levo gel 5%, for the treatment of acne vulgaris. These trials aim to evaluate the safety and effectiveness of this new drug when applied once daily for various durations, ranging from 12 to 52 weeks. The studies include patients aged 9 to 50 years with facial and, in some cases, truncal acne vulgaris.

Related diseases and areas:

• Acne

(S)-4-(4-(3-CHLORO-4-(1-(5-FLUOROPYRIDIN-2-YL)-2-HYDROXYETHOXY)PYRAZOLO[1,5-A]PYRIDIN-6-YL)-5-METHYL-1H-1,2,3-TRIAZOL-1-YL)PIPERIDINE-1-CARBONITRILE

Clinical trials are investigating “(S)-4-(4-(3-CHLORO-4-(1-(5-FLUOROPYRIDIN-2-YL)-2-HYDROXYETHOXY)PYRAZOLO[1,5-A]PYRIDIN-6-YL)-5-METHYL-1H-1,2,3-TRIAZOL-1-YL)PIPERIDINE-1-CARBONITRILE” in people with cancer in the urinary tract, especially advanced bladder cancer. These studies aim to assess safety and whether the treatment helps control the cancer. The main trial listed is a Phase 3 study.

(S)-4,5-Dihydro-2-[2-Hydroxy-4-(3,6-Dioxaheptyloxy)Phenyl]-4-Methyl-4-Thiazolecarboxylic Acid

This article discusses the ongoing clinical trials of SP-420, a novel drug being tested for the treatment of transfusion-dependent alpha or beta thalassemia. SP-420 is being evaluated in an open-label, dose-escalation, dose-finding, and proof-of-concept trial to assess its effectiveness in removing excess iron from the body and improving the quality of life for patients with these blood disorders.

Related diseases and areas:

• Thalassaemia beta
• Thalassaemia alpha

(S)-N-(5-(4-(1-(Benzo[D][1,3]Dioxol-5-Yl)Ethyl)Piperazin-1-Yl)-1,3,4-Thiadiazol-2-Yl)Acetamide, Hydrochloride Salt

This article discusses a clinical trial investigating the use of a new drug called FNP-223 in patients with Progressive Supranuclear Palsy (PSP). The study aims to assess the safety, effectiveness, and pharmacokinetics of FNP-223 in slowing the progression of PSP. This Phase 2 trial is randomized, double-blind, and placebo-controlled, involving patients aged 50 to 80 years with possible or probable PSP.

Related diseases and areas:

• Progressive supranuclear palsy

[(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL

This article discusses clinical trials investigating [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL (also known as DZD8586), an investigational drug being studied for blood cancers. Current research focuses on a Phase 3 trial evaluating its anti-tumor efficacy in patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Related diseases and areas:

• Chronic lymphocytic leukaemia
• Streptococcal infection
• B-cell small lymphocytic ly…

[14C] DC-806

Clinical trials of “[14C] DC-806” are studying how the body removes it, how it moves through the body, and how it is broken down. The trial data describe a Phase 1 study in healthy male participants, with goals focused on excretion, mass balance, and pharmacokinetics after a single oral dose.

Related diseases and areas:

• Psoriasis

[14C]ZIPALERTINIB

This article discusses clinical trials investigating [14C]ZIPALERTINIB, a radiolabeled form of the drug zipalertinib. The trials aim to evaluate how the body processes this substance by measuring mass balance, pharmacokinetics, and metabolism. These Phase 1 studies involve healthy adult male volunteers and help researchers understand drug distribution, elimination, and breakdown in the human body.

Related diseases and areas:

• Non-small cell lung cancer

[188Re]-Bis(Perthiobenzoato)(Dithiobenzoato)Rhenium (Iii)

This article discusses a phase II clinical trial investigating the effectiveness of 188Re-SSS Lipiodol, a radiopharmaceutical containing [188Re]-Bis(Perthiobenzoato)(Dithiobenzoato)Rhenium (III), for treating non-operable hepatocellular carcinoma (liver cancer). The study aims to evaluate the efficacy of this treatment using Selective Internal Radiation Therapy (SIRT) in patients who cannot undergo surgery. The trial focuses on assessing tumor response, survival rates, and safety of this innovative approach for liver cancer patients with limited treatment options.

Related diseases and areas:

• Hepatocellular carcinoma

[18F]-Altanserin

This article discusses a clinical trial investigating the role of the serotonergic system in controlling impulsivity in adults with Tourette Syndrome. The study uses [18F]-Altanserin, a radioactive tracer, in PET imaging to examine the availability of serotonin 5-HT2A receptors in the brain. The research aims to understand how these receptors relate to impulsivity and other behavioral changes in patients undergoing routine treatment for Tourette Syndrome.

Related diseases and areas:

• Tourette’s disorder

[18F]CPFPX

Clinical trials investigating “[18F]CPFPX” are studying its use in brain imaging for people with drug-resistant epilepsy and healthy volunteers. The main goal is to compare brainstem findings under a breathing-related challenge and learn more about arousal and respiratory control. These studies are in Phase 2 and focus on safety-related research questions and biological markers measured by PET imaging.

[18F]DED

This article discusses clinical trials investigating [18F]DED, a brain imaging agent used in PET scans. Researchers are studying [18F]DED to understand early changes in dementia-related diseases and other neurodegenerative conditions. The trials aim to characterize how this imaging agent works in patients along the Alzheimer’s disease continuum and evaluate its potential for detecting brain changes.

Related diseases and areas:

• Dementia
• Prodromal Alzheimer’s disease
• CADASIL

[18F]Fapi-74

[18F]Fapi-74 is an innovative radioactive tracer being studied in clinical trials for its potential to improve cancer detection and diagnosis. This article explores how [18F]Fapi-74 is being used in PET/CT imaging to detect cancer spread and evaluate treatment effectiveness in patients with pancreatic, colon, prostate, and other cancers. We’ll discuss the ongoing research, potential benefits, and what patients can expect from these trials.

Related diseases and areas:

• Connective tissue disorder

[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone

This article explores the ongoing clinical trials of BI 764198, a novel drug being investigated for the treatment of focal segmental glomerulosclerosis (FSGS), a type of kidney disease. The trials aim to assess the efficacy, safety, and tolerability of BI 764198 in patients with FSGS, as well as its pharmacokinetic and pharmacodynamic profile. This research could potentially lead to a new treatment option for individuals suffering from this challenging kidney condition.

Related diseases and areas:

• Focal segmental glomerulosc…

[4-(METHYL-1H-PYRAZOL-4-YL)-BENZYL]-(6[7-(3-PYRROLIDIN-1-YL-PROPOXY)-IMIDAZO[1,2-A]PYRIDIN-3-YL]-PYRIMIDIN-4-YL]-AMINE

This article discusses a Phase 3 clinical trial investigating [4-(METHYL-1H-PYRAZOL-4-YL)-BENZYL]-(6[7-(3-PYRROLIDIN-1-YL-PROPOXY)-IMIDAZO[1,2-A]PYRIDIN-3-YL]-PYRIMIDIN-4-YL]-AMINE (also known as IDRX-42 or GSK6042981) for patients with metastatic or unresectable gastrointestinal stromal tumors (GIST) who have not responded to imatinib treatment. The trial aims to evaluate whether this investigational drug is more effective than sunitinib in preventing disease progression.

[89Zr]Bms-986279

This article discusses a clinical trial investigating the use of [89Zr]BMS-986279, also known as Anti-Fucosyl GM1 PET Tracer, in combination with other drugs for the treatment of extensive-stage small cell lung cancer. The study aims to evaluate the safety, effectiveness, and potential benefits of this new combination therapy compared to standard treatment approaches.

Related diseases and areas:

• Small cell lung cancer exte…

[89ZR]ZR-DFO-CIT-013

This article discusses clinical trials investigating [89Zr]Zr-DFO-CIT-013, a radiolabeled imaging agent used in PET-CT scans. The trials aim to evaluate how this substance distributes throughout the body in patients with inflammatory mediated immune diseases (IMIDs). The research focuses on understanding the uptake patterns of [89Zr]Zr-DFO-CIT-013 in different organs and comparing these patterns across various inflammatory conditions.

[99MTC]PSMA I&S

This article discusses clinical trials investigating [99mTc]PSMA I&S, a radioactive imaging agent used during surgery for prostate cancer. The trials aim to evaluate whether this substance can help surgeons better identify lymph node involvement in patients undergoing robot-assisted radical prostatectomy. The research focuses on patients with prostate cancer who have a higher risk of lymph node spread.

[Ala1,3,12,Gln10,Arg11,Trp14]Pth(1-14)/[Ala18,22, Lys26]Pthrp(15-36)Cooh

This article discusses the ongoing clinical trials of eneboparatide (AZP-3601), a novel parathyroid hormone receptor agonist, for the treatment of chronic hypoparathyroidism. The CALYPSO study is a Phase 3 multicenter, randomized, placebo-controlled, double-blind trial aimed at assessing the efficacy and safety of eneboparatide in patients with this rare endocrine disorder. The trials focus on evaluating the drug’s ability to reduce the need for active vitamin D and calcium supplements while maintaining normal serum calcium levels.

Related diseases and areas:

• Hypoparathyroidism